Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ACRS Aclaris Therapeutics
14.080+0.350+2.55%
Close
02/07 16:00 ET
14.0800.0000.00%
Post Mkt Price 02/07 16:01 ET
High
14.160
Open
13.910
Turnover
12.96M
Low
13.610
Pre Close
13.730
Volume
931.86K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Analysts Are Bullish on Top Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Aclaris Therapeutics (ACRS)
Aclaris Therapeutics Price Target Maintained With a $38.00/Share by Cantor Fitzgerald
Aclaris Therapeutics Price Target Maintained With a $38.00/Share by Cantor Fitzgerald
Aclaris Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/07/2023 176.77% Cantor Fitzgerald → $38 Reiterates → Overweight 12/14/2022 111.22% Stifel → $29 Initiat
Cantor Fitzgerald Reiterates Overweight on Aclaris Therapeutics, Maintains $38 Price Target
Cantor Fitzgerald analyst Louise Chen reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Overweight and maintains $38 price target.
Analysts Conflicted on These Healthcare Names: Mednax (MD), Aclaris Therapeutics (ACRS) and Eli Lilly & Co (LLY)
Aclaris Therapeutics (NASDAQ:ACRS) Shares Gap Up to $14.33
Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Rating) shares gapped up prior to trading on Friday . The stock had previously closed at $14.33, but opened at $14.81. Aclaris Therapeutics shares last t
Even Though Aclaris Therapeutics (NASDAQ:ACRS) Has Lost US$229m Market Cap in Last 7 Days, Shareholders Are Still up 998% Over 3 Years
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) shareholders might be concerned after seeing the share price drop 20% in the last week. But over the last three years the stock has shone bright like a diam
Insider Sell: Aclaris Therapeutics
05:11 PM EST, 02/03/2023 (MT Newswires) -- Neal Walker, Director, on February 01, 2023, sold 30,000 shares in Aclaris Therapeutics (ACRS) for $499,923. Following the Form 4 filing with the SEC, Walker
Aclaris Therapeutics (NASDAQ:ACRS) Sees Large Volume Increase
Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Rating) shares saw unusually-strong trading volume on Friday . Approximately 758,008 shares traded hands during mid-day trading, an increase of 107% from
Aclaris Therapeutics (NASDAQ:ACRS) Sees Strong Trading Volume
Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Rating) shares saw an uptick in trading volume on Friday . 758,008 shares were traded during trading, an increase of 107% from the previous session's vo
Company Overview
More
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.
CEO： Mr. Douglas J. Manion
Market： NASDAQ
Listing Date： 10/07/2015
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet